Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Kevin Danahy is recorded as CEO at Pulse Biosciences, Inc. (PLSE). Pulse Biosciences, Inc. reported in an 8-K filed May 15, 2024 that Kevin Danahy was appointed Chief Commercial Officer. Pulse Biosciences, Inc. reported in an 8-K filed May 15, 2024 that Kevin Danahy was appointed Chief Commercial Officer, effective May 14, 2024. Pulse Biosciences, Inc. reported in an 8-K filed September 28, 2022 that Kevin Danahy was appointed Chief Executive Officer, effective September 20, 2022. Equibles holds 4 filed executive changes naming Kevin Danahy; each is listed under recent activity with its source filing. Kevin Danahy has spoken on 6 earnings calls across 1 company, most recently for Pulse Biosciences, Inc. on March 28, 2024.
“Concurrently, the Company announced the appointment of Kevin Danahy, former President and Chief Executive Officer, as Chief Commercial Officer.”
“Concurrently, the Company announced the appointment of Kevin Danahy, former President and Chief Executive Officer, as Chief Commercial Officer.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2022-09-20–present
SEC 8-K
2022-02-14–present
Recorded roles and call appearances connecting this person to public companies.
CEO
2022-02-14–present
Other people whose current roles at this company are on record from its filings.
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
